BASTIDE: Groupe Bastide records revenue of EUR 223 million in the 1st half of 2021-2022, boosted by more technically demanding businesses – 02/07/2022 at 18:30

• Limitation of the exposure of the Group’s overall activity to the EHPAD sector to less than 17% of annual turnover in France
  

• Continuation of the development dynamic in more technically demanding businesses and internationally
  

Caissargues, February 7, 2022 – 5:45 p.m. CET – Bastide Le Confort Médical (Euronext Paris Compartment B: BLC, FR0000035370), home healthcare provider, announces its turnover for the second quarter and first half of 2021/2022.

Vincent Bastide, Chairman and CEO of the BASTIDE Group declares:

“This good half-year performance, despite an exceptionally unfavorable base effect, demonstrates the strong potential of our new strategy. The exposure of the Group’s overall activity remains very limited to the sector of private, public or associative EHPADs, which represents less than 17% of overall turnover in France, and none of the customers in this sector weigh more than 5 % of overall annual turnover. While remaining faithful to its historical customers, the Bastide Group continues to direct its activities towards the management of acute and chronic illnesses at home, such as respiratory assistance or nutrition-infusion, in line with the evolution of care. at home which require an ever greater quality requirement. At the same time, we will continue our internationalization, adapting our know-how to highly technical services and to an increasingly diversified clientele and methods of remuneration. The agility of the Bastide Group enables it to meet this challenge from which it can only emerge with higher profitability and growth potential. »

Despite an unfavorable base effect linked to the impact of the health crisis on the 1

^er

half of the previous financial year, which had seen a strong increase in sales of medical devices and personal protective equipment, the turnover of the 1

^er

semester 2021/2022 shows a slight increase of nearly +1% to €223 million.

As at 1

^er

quarter, the “Respiratory” activity continued its solid growth, while the “Home care” activity returned to its pre-health crisis level.

Thereby,

the “Home care” activity

achieves half-year revenue of €100.9 million, down 15% compared to a 1

^er

semester 2020/2021 which had benefited from a favorable Covid-19 effect due to the sale of personal protective equipment (PPE), the latter consequently showing a drop in sales of more than 83% over this semester. Restated for this PPE effect, the “MAD” business grew by +6%.

• In local authorities, the Group posted revenue of €46.9 million, down -18% on an organic basis due to a lower contribution from sales linked to the health crisis and up +11% excluding this effect. . Furthermore, the Group specifies that the exposure of this activity to the EHPAD sector remains more than limited, and that the Group has continued to strengthen its links with its customers in this activity which contributes very little to the Group’s margin.

• In stores/subsidiaries, turnover amounted to €54.0 million, down -13% due to the decline in PPE sales, but shows an increase of 2% once this impact is restated. This weaker performance in the stores is increasingly offset by the strong growth in Internet sales, which is confirmed by the evolution of the overall business mix.

“Breathing” activity

continued its strong growth to reach 1

^er

half-year to €64.4 million in revenue, posting an increase of +20% in published data and +14% in organic terms. All of the international subsidiaries continued to contribute to this solid performance this semester, driven by Baywater in the United Kingdom and by Keylab Medical in Spain.

The “Nutrition-Perfusion-Diabetes-Stomatherapy” activity

confirms its very good orientation with a turnover of €57.7 million, up by +19%, of which +8% organically. The Perfusion and Nutrition businesses continue to drive the division with organic growth of +11%. The return to growth in Diabetes is confirmed with growth of 2%, while sales in stoma therapy posted solid organic growth of 6%.

Outlook 2021-2022

at the end of its first half of 2021/2022, the Group reconfirms its revenue target of €460 million on a like-for-like basis accompanied by a current operating margin above 8.3%, taking into account the favorable evolution of the product mix and despite price reductions in Respiratory (sleep apnea) and Diabetes services. In the current context, the Group will accelerate its external growth strategy in order to strengthen its positions both internationally and in more technically demanding businesses, less dependent on regulatory pricing pressures.

About Bastide Medical Comfort Group

Created in 1977 by Guy Bastide, the BASTIDE Group is one of the main European players in home healthcare services. Present in 5 countries, BASTIDE develops a permanent quality approach and is committed to providing medical devices and associated services that best meet the needs of patients in key health areas: diabetes, nutrition, infusion, respiratory, stomatherapy and urology. . BASTIDE is listed on Euronext Paris (ISIN: FR0000035370, Reuters BATD.PA, – Bloomberg BLC: FP).

1

Organic growth calculated at constant exchange rates and at constant scope, restating 2020-2021 for the contribution of companies acquired less than 12 months ago

© Copyright Actusnews Wire

Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com